دورية أكاديمية
Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update.
| العنوان: | Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update. |
|---|---|
| المؤلفون: | Soares A; Latin American Cooperative Oncology Group, Genitourinary Group (LACOG-GU), Av. Brigadeiro Faria Lima, Vila Olímpia, São Paulo, SP, 4300, Brazil. dr.andrey@uol.com.br.; Hospital Israelita Albert Einstein, São Paulo, SP, Brazil. dr.andrey@uol.com.br.; Centro Paulista de Oncologia/Oncoclínicas, São Paulo, SP, Brazil. dr.andrey@uol.com.br., Monteiro FSM; Latin American Cooperative Oncology Group, Genitourinary Group (LACOG-GU), Av. Brigadeiro Faria Lima, Vila Olímpia, São Paulo, SP, 4300, Brazil.; Hospital Sírio-Libanês, Brasília, DF, Brazil., da Trindade KM; Latin American Cooperative Oncology Group, Genitourinary Group (LACOG-GU), Av. Brigadeiro Faria Lima, Vila Olímpia, São Paulo, SP, 4300, Brazil.; Oncologia D'Or, Fortaleza, CE, Brazil., Silva AGE; Latin American Cooperative Oncology Group, Genitourinary Group (LACOG-GU), Av. Brigadeiro Faria Lima, Vila Olímpia, São Paulo, SP, 4300, Brazil.; Instituto do Câncer e Transplante de Curitiba/PR (ICTr Curitiba), Curitiba, PR, Brazil., Cardoso APG; Latin American Cooperative Oncology Group, Genitourinary Group (LACOG-GU), Av. Brigadeiro Faria Lima, Vila Olímpia, São Paulo, SP, 4300, Brazil.; Hospital Israelita Albert Einstein, São Paulo, SP, Brazil., Sasse AD; Latin American Cooperative Oncology Group, Genitourinary Group (LACOG-GU), Av. Brigadeiro Faria Lima, Vila Olímpia, São Paulo, SP, 4300, Brazil.; Grupo SONHE de Campinas, Campinas, SP, Brazil., Fay AP; Latin American Cooperative Oncology Group, Genitourinary Group (LACOG-GU), Av. Brigadeiro Faria Lima, Vila Olímpia, São Paulo, SP, 4300, Brazil.; Escola de Medicina da Pontifícia, Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, RS, Brazil., Carneiro APCD; Latin American Cooperative Oncology Group, Genitourinary Group (LACOG-GU), Av. Brigadeiro Faria Lima, Vila Olímpia, São Paulo, SP, 4300, Brazil.; Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.; Hospital Municipal Vila Santa Catarina, São Paulo, SP, Brazil., Alencar Junior AM; Latin American Cooperative Oncology Group, Genitourinary Group (LACOG-GU), Av. Brigadeiro Faria Lima, Vila Olímpia, São Paulo, SP, 4300, Brazil.; Hospital São Domingos, São Luís, MA, Brazil.; Dasa Oncologia, Brasília, DF, Brazil.; Hospital Universitário da Universidade Federal do Maranhão (UFMA), São Luís, MA, Brazil., de Andrade Mota AC; Latin American Cooperative Oncology Group, Genitourinary Group (LACOG-GU), Av. Brigadeiro Faria Lima, Vila Olímpia, São Paulo, SP, 4300, Brazil.; Clínica AMO-DASA, Feira de Santana, BA, Brazil., Santucci B; Latin American Cooperative Oncology Group, Genitourinary Group (LACOG-GU), Av. Brigadeiro Faria Lima, Vila Olímpia, São Paulo, SP, 4300, Brazil.; Instituto Paulista de Cancerologia, São Paulo, SP, Brazil., da Motta Girardi D; Latin American Cooperative Oncology Group, Genitourinary Group (LACOG-GU), Av. Brigadeiro Faria Lima, Vila Olímpia, São Paulo, SP, 4300, Brazil.; Hospital Sírio-Libanês, Brasília, DF, Brazil., Herchenhorn D; Latin American Cooperative Oncology Group, Genitourinary Group (LACOG-GU), Av. Brigadeiro Faria Lima, Vila Olímpia, São Paulo, SP, 4300, Brazil.; Oncologia D'Or, Rio de Janeiro, RJ, Brazil., Araújo DV; Latin American Cooperative Oncology Group, Genitourinary Group (LACOG-GU), Av. Brigadeiro Faria Lima, Vila Olímpia, São Paulo, SP, 4300, Brazil.; Hospital de Base de São José do Rio Preto/SP, São José do Rio Preto, São Paulo, SP, Brazil., Jardim DL; Latin American Cooperative Oncology Group, Genitourinary Group (LACOG-GU), Av. Brigadeiro Faria Lima, Vila Olímpia, São Paulo, SP, 4300, Brazil.; Grupo Oncoclínicas, São Paulo, São Paulo, SP, Brazil., Bastos DA; Latin American Cooperative Oncology Group, Genitourinary Group (LACOG-GU), Av. Brigadeiro Faria Lima, Vila Olímpia, São Paulo, SP, 4300, Brazil.; Hospital Sirio-Libanês de São Paulo, São Paulo, SP, Brazil., Rosa DR; Latin American Cooperative Oncology Group, Genitourinary Group (LACOG-GU), Av. Brigadeiro Faria Lima, Vila Olímpia, São Paulo, SP, 4300, Brazil.; Grupo Oncoclínicas, Rio de Janeiro, RJ, Brazil., Schutz FA; Latin American Cooperative Oncology Group, Genitourinary Group (LACOG-GU), Av. Brigadeiro Faria Lima, Vila Olímpia, São Paulo, SP, 4300, Brazil.; Beneficência Portuguesa de São Paulo, São Paulo, SP, Brazil., Kater FR; Latin American Cooperative Oncology Group, Genitourinary Group (LACOG-GU), Av. Brigadeiro Faria Lima, Vila Olímpia, São Paulo, SP, 4300, Brazil.; Beneficência Portuguesa de São Paulo, São Paulo, SP, Brazil., da Silva Marinho F; Latin American Cooperative Oncology Group, Genitourinary Group (LACOG-GU), Av. Brigadeiro Faria Lima, Vila Olímpia, São Paulo, SP, 4300, Brazil.; Grupo Oncoclínicas, Recife, PE, Brazil., Maluf FC; Latin American Cooperative Oncology Group, Genitourinary Group (LACOG-GU), Av. Brigadeiro Faria Lima, Vila Olímpia, São Paulo, SP, 4300, Brazil.; Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.; Beneficência Portuguesa de São Paulo, São Paulo, SP, Brazil., de Oliveira FNG; Latin American Cooperative Oncology Group, Genitourinary Group (LACOG-GU), Av. Brigadeiro Faria Lima, Vila Olímpia, São Paulo, SP, 4300, Brazil.; Grupo Oncoclínicas, Salvador, BA, Brazil., Vidigal F; Latin American Cooperative Oncology Group, Genitourinary Group (LACOG-GU), Av. Brigadeiro Faria Lima, Vila Olímpia, São Paulo, SP, 4300, Brazil.; Dasa Oncologia, Brasília, DF, Brazil., Morbeck IAP; Latin American Cooperative Oncology Group, Genitourinary Group (LACOG-GU), Av. Brigadeiro Faria Lima, Vila Olímpia, São Paulo, SP, 4300, Brazil.; Grupo Oncoclínicas, Brasília, DF, Brazil., Rinck Júnior JA; Latin American Cooperative Oncology Group, Genitourinary Group (LACOG-GU), Av. Brigadeiro Faria Lima, Vila Olímpia, São Paulo, SP, 4300, Brazil.; AC Camargo Cancer Center, São Paulo, SP, Brazil., Costa LAGA; Latin American Cooperative Oncology Group, Genitourinary Group (LACOG-GU), Av. Brigadeiro Faria Lima, Vila Olímpia, São Paulo, SP, 4300, Brazil.; Oncologia D'Or, Fortaleza, CE, Brazil., Maia MCDF; Latin American Cooperative Oncology Group, Genitourinary Group (LACOG-GU), Av. Brigadeiro Faria Lima, Vila Olímpia, São Paulo, SP, 4300, Brazil.; Hospital do Câncer Porto Dias, Belém, PA, Brazil., Zereu M; Latin American Cooperative Oncology Group, Genitourinary Group (LACOG-GU), Av. Brigadeiro Faria Lima, Vila Olímpia, São Paulo, SP, 4300, Brazil.; Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, RS, Brazil., Freitas MRP; Latin American Cooperative Oncology Group, Genitourinary Group (LACOG-GU), Av. Brigadeiro Faria Lima, Vila Olímpia, São Paulo, SP, 4300, Brazil.; Centro Especializado de Oncologia de Florianópolis, Florianópolis, SC, Brazil., Dias MSF; Latin American Cooperative Oncology Group, Genitourinary Group (LACOG-GU), Av. Brigadeiro Faria Lima, Vila Olímpia, São Paulo, SP, 4300, Brazil.; Grupo Oncoclínicas, Rio de Janeiro, RJ, Brazil., Tariki MS; Latin American Cooperative Oncology Group, Genitourinary Group (LACOG-GU), Av. Brigadeiro Faria Lima, Vila Olímpia, São Paulo, SP, 4300, Brazil.; AC Camargo Cancer Center, São Paulo, SP, Brazil., Muniz P; Latin American Cooperative Oncology Group, Genitourinary Group (LACOG-GU), Av. Brigadeiro Faria Lima, Vila Olímpia, São Paulo, SP, 4300, Brazil.; Grupo Oncoclínicas, São Paulo, São Paulo, SP, Brazil.; Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil., Beato PMM; Latin American Cooperative Oncology Group, Genitourinary Group (LACOG-GU), Av. Brigadeiro Faria Lima, Vila Olímpia, São Paulo, SP, 4300, Brazil.; Hospital Amaral Carvalho, Jaú, SP, Brazil., Lages PSM; Latin American Cooperative Oncology Group, Genitourinary Group (LACOG-GU), Av. Brigadeiro Faria Lima, Vila Olímpia, São Paulo, SP, 4300, Brazil.; Grupo Oncoclínicas, Brasília, DF, Brazil., Velho PI; Latin American Cooperative Oncology Group, Genitourinary Group (LACOG-GU), Av. Brigadeiro Faria Lima, Vila Olímpia, São Paulo, SP, 4300, Brazil.; Hospital Moinhos de Vento, Porto Alegre, RS, Brazil.; Johns Hopkins University, Baltimore, MD, USA., de Carvalho RS; Latin American Cooperative Oncology Group, Genitourinary Group (LACOG-GU), Av. Brigadeiro Faria Lima, Vila Olímpia, São Paulo, SP, 4300, Brazil.; Beneficência Portuguesa de São Paulo, São Paulo, SP, Brazil., Mariano RC; Latin American Cooperative Oncology Group, Genitourinary Group (LACOG-GU), Av. Brigadeiro Faria Lima, Vila Olímpia, São Paulo, SP, 4300, Brazil.; Beneficência Portuguesa de São Paulo, São Paulo, SP, Brazil., de Araújo Cavallero SR; Latin American Cooperative Oncology Group, Genitourinary Group (LACOG-GU), Av. Brigadeiro Faria Lima, Vila Olímpia, São Paulo, SP, 4300, Brazil.; Hospital Adventista de Belém, Belém, PA, Brazil., Oliveira TM; Latin American Cooperative Oncology Group, Genitourinary Group (LACOG-GU), Av. Brigadeiro Faria Lima, Vila Olímpia, São Paulo, SP, 4300, Brazil.; Hospital São Rafael, Salvador, BA, Brazil., Souza VC; Latin American Cooperative Oncology Group, Genitourinary Group (LACOG-GU), Av. Brigadeiro Faria Lima, Vila Olímpia, São Paulo, SP, 4300, Brazil.; Instituto D'Or de Ensino e Pesquisa, Salvador, BA, Brazil., Smaletz O; Latin American Cooperative Oncology Group, Genitourinary Group (LACOG-GU), Av. Brigadeiro Faria Lima, Vila Olímpia, São Paulo, SP, 4300, Brazil.; Hospital Israelita Albert Einstein, São Paulo, SP, Brazil., de Cássio Zequi S; AC Camargo Cancer Center, São Paulo, SP, Brazil.; National Institute for Science and Technology in Oncogenomics and Therapeutic Innovation, AC Camargo Cancer Center, São Paulo, SP, Brazil. |
| المصدر: | Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2024 Apr 09; Vol. 150 (4), pp. 183. Date of Electronic Publication: 2024 Apr 09. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 7902060 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-1335 (Electronic) Linking ISSN: 01715216 NLM ISO Abbreviation: J Cancer Res Clin Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Berlin ; New York : Springer-Verlag. |
| مواضيع طبية MeSH: | Carcinoma, Renal Cell*/drug therapy , Carcinoma, Renal Cell*/pathology , Kidney Neoplasms*/drug therapy , Kidney Neoplasms*/pathology, Humans ; Latin America ; Consensus ; Sunitinib |
| مستخلص: | Purpose: Renal cell carcinoma is an aggressive disease with a high mortality rate. Management has drastically changed with the new era of immunotherapy, and novel strategies are being developed; however, identifying systemic treatments is still challenging. This paper presents an update of the expert panel consensus from the Latin American Cooperative Oncology Group and the Latin American Renal Cancer Group on advanced renal cell carcinoma management in Brazil. Methods: A panel of 34 oncologists and experts in renal cell carcinoma discussed and voted on the best options for managing advanced disease in Brazil, including systemic treatment of early and metastatic renal cell carcinoma as well as nonclear cell tumours. The results were compared with the literature and graded according to the level of evidence. Results: Adjuvant treatments benefit patients with a high risk of recurrence after surgery, and the agents used are pembrolizumab and sunitinib, with a preference for pembrolizumab. Neoadjuvant treatment is exceptional, even in initially unresectable cases. First-line treatment is mainly based on tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs); the choice of treatment is based on the International Metastatic Database Consortium (IMCD) risk score. Patients at favourable risk receive ICIs in combination with TKIs. Patients classified as intermediate or poor risk receive ICIs, without preference for ICI + ICIs or ICI + TKIs. Data on nonclear cell renal cancer treatment are limited. Active surveillance has a place in treating favourable-risk patients. Either denosumab or zoledronic acid can be used for treating metastatic bone disease. Conclusion: Immunotherapy and targeted therapy are the standards of care for advanced disease. The utilization and sequencing of these therapeutic agents hinge upon individual risk scores and responses to previous treatments. This consensus reflects a commitment to informed decision-making, drawn from professional expertise and evidence in the medical literature. (© 2024. The Author(s).) |
| References: | Clin Genitourin Cancer. 2017 Oct;15(5):e897-e901. (PMID: 28645484) J Urol. 2009 Feb;181(2):518-23; discussion 523. (PMID: 19100579) J Cancer Res Clin Oncol. 2014 Aug;140(8):1421-8. (PMID: 24752340) J Clin Oncol. 2020 Dec 1;38(34):4064-4075. (PMID: 33052759) Clin Cancer Res. 2021 Jan 1;27(1):78-86. (PMID: 32873572) J Natl Compr Canc Netw. 2014 Nov;12(11):1517-23. (PMID: 25361798) Int J Clin Pharm. 2021 Feb;43(1):2-10. (PMID: 32964403) N Engl J Med. 2021 Mar 4;384(9):829-841. (PMID: 33657295) Lancet Oncol. 2015 Nov;16(15):1473-1482. (PMID: 26482279) Transl Oncol. 2020 Feb;13(2):241-244. (PMID: 31869748) Clin Genitourin Cancer. 2020 Dec;18(6):429-435. (PMID: 32800717) N Engl J Med. 2015 Nov 5;373(19):1803-13. (PMID: 26406148) J Bone Oncol. 2023 Feb 09;39:100470. (PMID: 36860585) N Engl J Med. 2016 Dec 8;375(23):2246-2254. (PMID: 27718781) N Engl J Med. 2013 Aug 22;369(8):722-31. (PMID: 23964934) Eur Urol. 2016 May;69(5):866-74. (PMID: 26626617) Cancer Treat Rev. 2012 Jun;38(4):284-91. (PMID: 21802857) N Engl J Med. 2021 Apr 8;384(14):1289-1300. (PMID: 33616314) Cancer Treat Res Commun. 2020 Feb 22;23:100169. (PMID: 32126518) Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):253-8. (PMID: 14697446) Front Oncol. 2022 Jul 15;12:906014. (PMID: 35912170) Int J Clin Oncol. 2018 Jun;23(3):559-567. (PMID: 29327159) Cancer Res Treat. 2018 Apr;50(2):488-494. (PMID: 28546525) Clin Genitourin Cancer. 2019 Dec;17(6):419-424. (PMID: 31585694) Cancers (Basel). 2020 Oct 06;12(10):. (PMID: 33036276) CA Cancer J Clin. 2022 Sep;72(5):454-489. (PMID: 35708940) Eur Urol. 2021 Aug;80(2):162-170. (PMID: 33867192) J Clin Oncol. 2017 Feb 20;35(6):591-597. (PMID: 28199818) Eur Urol Focus. 2019 May;5(3):474-481. (PMID: 29311016) J Clin Oncol. 2023 Jul 20;41(21):3767. (PMID: 37159880) Neuro Oncol. 2021 Aug 2;23(8):1261-1272. (PMID: 33631792) Ther Adv Med Oncol. 2020 Mar 18;12:1758835920907504. (PMID: 32215057) Expert Opin Pharmacother. 2013 Jun;14(9):1229-40. (PMID: 23578333) Clin Genitourin Cancer. 2023 Jun;21(3):324-333. (PMID: 36823017) J Clin Oncol. 1995 Mar;13(3):688-96. (PMID: 7884429) Clin Genitourin Cancer. 2021 Dec;19(6):521-530. (PMID: 34158246) J Immunother Cancer. 2022 Feb;10(2):. (PMID: 35210307) Lancet Oncol. 2016 Sep;17(9):1317-24. (PMID: 27498080) Clin Genitourin Cancer. 2022 Jun;20(3):285-295. (PMID: 35305916) J Clin Oncol. 2009 Dec 1;27(34):5794-9. (PMID: 19826129) Lancet. 2023 Jul 15;402(10397):185-195. (PMID: 37290461) Eur J Cancer. 2017 Sep;83:237-246. (PMID: 28756136) Eur J Cancer. 2019 Feb;108:33-40. (PMID: 30616146) Cancer. 2020 Sep 15;126(18):4156-4167. (PMID: 32673417) N Engl J Med. 2019 Mar 21;380(12):1116-1127. (PMID: 30779529) Cancer. 2011 Jun 1;117(11):2505-12. (PMID: 24048799) Cancer. 2022 Jun 1;128(11):2085-2097. (PMID: 35383908) Curr Oncol. 2013 Jun;20(3):e223-32. (PMID: 23737692) Target Oncol. 2023 Jul;18(4):559-570. (PMID: 37369815) Eur Urol. 2015 Apr;67(4):740-9. (PMID: 24882670) J Epidemiol Glob Health. 2022 Sep;12(3):239-247. (PMID: 35639266) Ther Clin Risk Manag. 2008 Feb;4(1):261-8. (PMID: 18728715) World J Oncol. 2020 Jun;11(3):79-87. (PMID: 32494314) Eur J Cancer. 2012 Feb;48(3):333-9. (PMID: 22209391) BMJ Open. 2019 Mar 1;9(3):e024691. (PMID: 30826762) Kidney Cancer. 2020;4(1):15-27. (PMID: 34435168) N Engl J Med. 2018 Apr 05;378(14):1277-1290. (PMID: 29562145) N Engl J Med. 2023 May 11;388(19):1767-1778. (PMID: 37163623) JCO Oncol Pract. 2022 Mar;18(3):187-196. (PMID: 34529499) ESMO Open. 2021 Jun;6(3):100101. (PMID: 33901870) JAMA Oncol. 2021 Dec 01;7(12):1815-1823. (PMID: 34673916) Eur J Cancer. 2019 Jun;114:67-75. (PMID: 31075726) Curr Urol Rep. 2019 Jan 17;20(1):4. (PMID: 30656488) ESMO Open. 2023 Jun;8(3):101210. (PMID: 37104931) Oncoimmunology. 2019 Apr 25;8(8):1606639. (PMID: 31413914) J Oncol Pharm Pract. 2019 Dec;25(8):1846-1852. (PMID: 31694497) Eur Urol. 2021 May;79(5):635-654. (PMID: 32798146) Curr Oncol. 2018 Oct;25(5):e444-e453. (PMID: 30464696) Br J Cancer. 2018 Jul;119(2):160-163. (PMID: 29795307) Lancet Oncol. 2021 Jul;22(7):946-958. (PMID: 34143969) PLoS One. 2016 Jun 06;11(6):e0155389. (PMID: 27271250) Lancet. 2021 Feb 20;397(10275):695-703. (PMID: 33592176) JAMA Oncol. 2017 Sep 01;3(9):1249-1252. (PMID: 28278333) Transl Androl Urol. 2020 Apr;9(2):367-381. (PMID: 32420142) Front Oncol. 2023 Mar 21;13:1133832. (PMID: 37025584) Can Urol Assoc J. 2015 Mar-Apr;9(3-4):E172-7. (PMID: 26085875) Arab J Urol. 2012 Jun;10(2):131-7. (PMID: 26558015) Eur Urol. 2021 Jul;80(1):20-31. (PMID: 33707112) N Engl J Med. 2019 Mar 21;380(12):1103-1115. (PMID: 30779531) Cancer. 2022 Mar 1;128(5):966-974. (PMID: 34784056) Urol Oncol. 2018 Dec;36(12):526.e13-526.e18. (PMID: 30301699) Lancet Oncol. 2023 Aug;24(8):881-891. (PMID: 37451291) Lancet Oncol. 2022 Jul;23(7):888-898. (PMID: 35688173) Eur Urol. 2012 Dec;62(6):1013-9. (PMID: 22771265) G Ital Nefrol. 2022 Jun 20;39(3):. (PMID: 35819037) N Engl J Med. 2021 Aug 19;385(8):683-694. (PMID: 34407342) Am Soc Clin Oncol Educ Book. 2020 Mar;40:1-10. (PMID: 32239988) J Oncol. 2015;2015:636918. (PMID: 26681942) J Cancer Res Clin Oncol. 2020 Jul;146(7):1829-1845. (PMID: 32410064) JCO Glob Oncol. 2021 May;7:671-685. (PMID: 33974442) Anticancer Res. 2019 Apr;39(4):2091-2095. (PMID: 30952754) CA Cancer J Clin. 2023 Jan;73(1):17-48. (PMID: 36633525) Eur J Cancer. 2018 Jul;98:38-47. (PMID: 29864737) Lancet. 2008 Aug 9;372(9637):449-56. (PMID: 18653228) Cancer. 2021 Jul 1;127(13):2204-2212. (PMID: 33765337) Eur Urol. 2017 Mar;71(3):426-436. (PMID: 27939075) Lancet Oncol. 2013 Feb;14(2):141-8. (PMID: 23312463) Lancet Oncol. 2022 Sep;23(9):1133-1144. (PMID: 36055304) Transl Androl Urol. 2020 Dec;9(6):2821-2830. (PMID: 33457253) Front Oncol. 2020 Sep 23;10:566070. (PMID: 33072598) PLoS One. 2017 Sep 8;12(9):e0184423. (PMID: 28886175) J Oncol Pract. 2017 Jul;13(7):414-421. (PMID: 28697319) Lancet. 2016 May 14;387(10032):2008-16. (PMID: 26969090) Cancers (Basel). 2019 Aug 03;11(8):. (PMID: 31382581) Lancet Oncol. 2016 Jul;17(7):917-927. (PMID: 27279544) Ann Oncol. 2018 Dec 1;29(12):2371-2378. (PMID: 30346481) Eur Urol. 2024 May 22;:. (PMID: 38782695) Oncologist. 2020 Mar;25(3):252-258. (PMID: 32162795) Eur Urol. 2021 Mar;79(3):334-338. (PMID: 33461782) J Clin Pharm Ther. 2021 Feb;46(1):35-49. (PMID: 33112003) Lancet. 2023 Mar 11;401(10379):821-832. (PMID: 36774933) Ann Oncol. 2017 Jun 01;28(6):1339-1345. (PMID: 28327953) |
| فهرسة مساهمة: | Keywords: Consensus; Immunotherapy; Metastatic disease; Renal cell carcinoma; Tyrosine kinase inhibitor; Vascular growth factor receptor |
| المشرفين على المادة: | V99T50803M (Sunitinib) |
| تواريخ الأحداث: | Date Created: 20240409 Date Completed: 20240411 Latest Revision: 20240525 |
| رمز التحديث: | 20240525 |
| مُعرف محوري في PubMed: | PMC11003910 |
| DOI: | 10.1007/s00432-024-05663-z |
| PMID: | 38594593 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1432-1335 |
|---|---|
| DOI: | 10.1007/s00432-024-05663-z |